TAG condemns the White House’s proposed retroactive $600 million cuts to CDC programs in four states. Because Congress already appropriated these funds, the cuts are illegal and unconstitutional, threatening HIV and public health programs nationwide. Congress must reject these partisan attacks and protect public health funding.
This National Black HIV/AIDS Awareness Day, Act Now: End AIDS and TAG uplift the truth: Black people are disproportionately impacted by HIV, and equity-driven solutions are essential. Ending the HIV epidemic requires confronting racism, expanding access to prevention and care, and ensuring that Black communities are centered, visible, and supported in public health efforts.
TAGLine 2025 documents a year of action as Treatment Action Group defended science, confronted attacks on public health, and fought to protect communities impacted by HIV, TB, and HCV.
Behind many lifesaving vaccines is a fragile supply chain that few people ever see. This new TAG report examines how weaknesses in the production and supply of key vaccine adjuvants (an ingredient that enhances the immune response) can create bottlenecks that threaten global access to vaccines, underscoring the importance of greater market transparency, security, and competitiveness among governments, funders, and pharmaceutical companies.
From Forest to Factory: Tracing the Supply Chains for Two Modern Adjuvants of Global Health Importance — QS-21 and MPL provides a first of its kind analysis of the global supply chains of two key adjuvants used in several of the world’s most important vaccines.
TAG sent this comment to the Centers for Disease Control and Prevention (CDC) September 2025 meeting on how to leverage same-day diagnosis and treatment for hepatitis C.
On June 5, 2025, TAG and WHO cohosted a webinar orienting people to long-acting injectables for TB treatment and prevention. Long-acting Injectables (LAIs) have the potential to revolutionize treatment for TB and other infectious diseases.
This publication discusses findings from two surveys conducted among end users and healthcare providers/policy makers to understand their perspectives on, and the facilitators and barriers to potential long-acting therapies for Hepatitis C virus (HCV) cure currently being developed by the LONGEVITY consortium, funded by the global health agency Unitaid.
This webinar will provide a platform to learn about the findings from the Longevity HCV and TB end users and healthcare providers/policy makers surveys, and for community members, especially marginalized populations across the world, to engage with the researchers developing these Long-Acting Therapies.
The new 2025 update of An Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis lays out what community advocates need to know about WHO-recommended regimens for drug-resistant TB.